Avastin for myopic CNV

Article

Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study

Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study from the February 2009 issue of the British Journal of Ophthalmology.

Please click here to read the full story.

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Related Content
Hemoglobin molecule structure, rendered in pink and purple. Generative AI. Image credit: ©Electro Unicorn – stock.adobe.com

TEASE-3 study: Positive interim data are reported for Stargardt drug

April 25th 2024
Article

Gildeuretinol halts Stargardt disease progression, study results indicate

Site Logo

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

June 29th 2023
Podcast
Professor Ramin Tadayoni, MD, PhD. Image courtesy of EURETINA

Retina community mourns sudden loss of Ramin Tadayoni, MD, PhD

April 22nd 2024
Article

Prof Tadayoni was a much-admired leader, researcher, surgeon and EURETINA President

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022
Podcast
Concept image for an exhibition hall crowded with people. Image credit: ©arhendrix – stock.adobe.com

Clinicians and researchers don’t shy away from hot topics in the field

April 18th 2024
Article

The 15th annual Congress on Controversies in Ophthalmology heads to Athens, Greece

Lohith Shetty. Image courtesy of SCHWIND

SCHWIND appoints new head of global marketing solutions

April 17th 2024
Article

Lohith Shetty will lead marketing for the company, based in Kleinostheim, Germany

© 2024 MJH Life Sciences

All rights reserved.